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Abstract
Background: Immunotherapy is revolutionising the treatment of patients diagnosed with melanoma and other
cancers. The first immune checkpoint inhibitor, ipilimumab (targeting cytotoxic T-lymphocyte-associated antigen 4
(CTLA-4)), showed a survival advantage over standard chemotherapy. Subsequently the anti-programmed cell death
protein 1 (PD-1) antibodies, nivolumab and pembrolizumab were shown to be more effective than ipilimumab.
Ipilimumab combined with nivolumab gives an incremental gain in overall survival compared with nivolumab
alone but increases the risk of severe, potentially life-threatening toxicities. In contrast to ipilimumab monotherapy,
anti-PD-1 antibodies are licensed to be continued until disease progression. Follow-up of patients recruited to the
first trials evaluating 2 years of pembrolizumab showed that three-quarters of responding patients continue
responding after stopping treatment. Suggestive of early response, we hypothesised that continuing anti-PD-1
treatment beyond 1 year in progression-free patients may be unnecessary and so designed the DANTE trial.
Methods: DANTE is a multicentre, randomised, phase III, non-inferiority trial to evaluate the duration of anti-PD-1
therapy in patients with metastatic (unresectable stage III and stage IV) melanoma. It uses a two-stage recruitment
strategy, registering patients before they complete 1 year of first-line anti-PD-1 +/− CTLA-4 therapy and
randomising eligible patients who have received 12 months of treatment and are progression-free at 1 year. At
randomisation, 1208 patients are assigned (1:1) to either 1) continue anti-PD-1 treatment until disease progression/
unacceptable toxicity/ for at least 2 years in the absence of disease progression/ unacceptable toxicity or 2) to stop
treatment. Randomisation stratifies for baseline prognostic factors. The primary outcome is progression-free survival
at 3, 6, 9 and 12 months and then, 6-monthly for up to 4-years. Secondary outcomes collected at all timepoints
include overall survival, response-rate and duration and safety, with quality of life and cost-effectiveness outcomes
collected 3-monthly for up to 18-months. Sub-studies include a qualitative analysis of patient acceptance of
randomisation and sample collection to inform future translational studies into response/ toxicity biomarkers.
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: s.danson@sheffield.ac.uk
9Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield, UK
10University of Sheffield, Sheffield, UK
Full list of author information is available at the end of the article
Coen et al. BMC Cancer          (2021) 21:761 
https://doi.org/10.1186/s12885-021-08509-w
Discussion: DANTE is a unique prospective trial investigating the optimal duration of anti-PD-1 therapy in
metastatic melanoma patients. Outcomes will inform future use of these high burden drugs.
Trial registration: ISRCTN15837212, 31 July 2018.
Keywords: Immunotherapy, Checkpoint inhibitor, Anti-PD-1, Metastatic melanoma, Schedule, Efficacy, Safety,
Quality of life
Background
Melanoma is the most aggressive form of skin cancer.
For most patients diagnosed with primary melanoma,
surgical excision alone is often sufficient with 1-year of
adjuvant systemic therapy reserved for higher risk pa-
tients. Systemic therapy is offered to those patients diag-
nosed with metastastic (unresectable stage III or stage
IV) disease. Until 2011, median survival was very poor at
around 8 months [1]. In the last decade, median overall
survival has increased now to around 3 years, due to the
introduction of 2 classes of systemic anticancer agents:
immune checkpoint inhibitors [2] and, in selected
BRAF-mutant patients, mitogen activated protein (MAP)
kinase pathway inhibitors [3].
Immune checkpoint inhibitors are now standard
practice across multiple tumour sites including melan-
oma [4], lung [5], head and neck [6] and urological
cancers [7,8]. In melanoma, therapeutic targets in-
clude the T cell receptors, cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) and programmed cell
death protein 1 (PD-1) [9].
Ipilimumab, directed against CTLA-4, was the first im-
mune checkpoint inhibitor to show improved overall
survival for patients with metastatic melanoma in both
the first-line [2] and second-line [10] setting. Subsequent
trials demonstrated greater survival benefit from PD-1
blockade using the antibodies pembrolizumab [11] or
nivolumab [12]. The CheckMate 067 trial compared ipi-
limumab combined with nivolumab for 12 weeks
followed by nivolumab maintenance with nivolumab
alone and with ipilimumab only and demonstrated 5 year
overall survival of 52% for combined therapy, 44% for
nivolumab monotherapy and 26% for ipilimumab after
minimum follow up of 60 months [13]. In contrast to
ipilimumab, which is given as 4 × 3 week infusions over
12 weeks, both pembrolizumab and nivolumab are li-
censed to continue regular infusions for as long as there
is clinical benefit or until unacceptable toxicity. Five year
outcomes of patients recruited to the KEYNOTE-001
trial [14] showed that while progression-free survival
(PFS) was around 8months, 29% of patients first treated
with pembrolizumab were progression free at 5 years.
Immune-checkpoint inhibitors have complex immune-
related side effects, which range from being mild to
potentially life threatening or life-changing. Onset most
likely occurs early however late-onset toxicity (beyond
12months) has previously been reported in 30% of pa-
tients completing a minimum treatment duration of 12
months [15]. The incidence of toxicity varies with regi-
men, with treatment related grade 3–4 adverse events
(AE) occurring in 23% of nivolumab-treated, 28% of ipi-
limumab–treated and 59% of ipilimumab-nivolumab-
treated patients [13]. Deaths are relatively rare [13].
In the UK, in line with current NICE guidance which
covers England, both pembrolizumab [16] and nivolumab
[17] are licensed monotherapies for first-line treatment of
patients with metastatic melanoma. Ipilimumab-
nivolumab is also licensed [18] and while there are no
clear specifications as to how to select between anti-PD-1
monotherapy and ipilimumab-nivolumab, increased rates
of toxicity mean ipilimumab-nivolumab is generally of-
fered to younger fitter patients [19].
Checkpoint inhibitors are high cost drugs, with signifi-
cant resource implications for clinical practice. The
question of whether anti-PD-1 antibodies need to be ad-
ministered chronically has been coming under increased
scrutiny. Long-term follow up data from previous stud-
ies however suggest that sustained responses can be seen
despite discontinuation of anti-PD-1 therapy. In the
phase III study of pembrolizumab (KEYNOTE-006), the
planned duration of treatment was 2 years with 19% of
patients completing treatment as planned (103 of 556
patients) [20]. In this group the estimated 24-month PFS
from completion of pembrolizumab was 78.4%, after a
median follow up of 34.2 months [20]. In those who pro-
gressed following completion of treatment as planned
(n = 27), 12 patients received further pembrolizumab
within the study [20]. Best overall response was
complete response (CR) in 3 patients, partial response
(PR) in 3 patients, stable disease (SD) in 3 patients, pro-
gressive disease (PD) in 1 patient and response assess-
ment pending in 2 patients [20]. Similar sustained
responses have also been observed with nivolumab use
in non-small cell lung cancer, with CheckMate 003 dem-
onstrating 5-year PFS in more than 75% of patients who
received time-limited treatment of 96 weeks [21]. These
trial results therefore support discontinuation of treat-
ment after a defined period of response without
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significant negative impact. Thus, many healthcare sys-
tems across the world have adopted a time-limited treat-
ment approach of stopping treatment after 2 years in
metastatic melanoma patients who remain progression-
free. However, these are small numbers and so a rando-
mised trial is warranted.
Evaluating the optimal duration of anti-PD-1 therapy
remains of clinical and health-economic interest due to
the impact of continued treatment on patient risk
through exposure to drug toxicity [22] or face-to-face
healthcare contacts as well as patient convenience and
resource use. Defining optimal duration has wide impli-
cations for the use of anti-PD-1 therapy which is being
rolled out across multiple tumour sites as well as being
used in earlier stages of disease. The DANTE trial serves
to compare stopping anti-PD-1 antibody therapy with
continuing treatment in those patients who are
progression-free at 1 year.
Methods/ design
Trial design
DANTE is a multicentre, randomised two-arm, parallel
group, unblinded, non-inferiority phase III trial compar-
ing time-limited treatment of 1 year of anti-PD-1 therapy
(experimental arm) to the current standard duration of
anti-PD-1 therapy (control arm), see Fig. 1. The ‘control’
arm of standard duration of anti-PD-1 therapy, consists
of treatment until disease progression/ unacceptable tox-
icity, or for 2 years or more in the absence of disease
progression or unacceptable toxicity, to allow generalis-
ability to the current UK melanoma practice. The trial
includes patients on nivolumab, pembrolizumab or
ipilimumab-nivolumab using a licensed dosing schedule,
reflecting variations across the UK and allowing greater
clinician and patient choice.
The trial is multistage with planned interim assess-
ments to ensure feasibility of recruitment (stages 1 and
2) and any lack of efficacy is identified early (stage 3),
with stop-continuation rules embedded into the trial de-
sign. Provided these conditions are met, primary analysis
of outcomes at 1-year post randomisation (stage 4) and
long-term analysis at 4-years post randomisation (stage
5) will occur. An embedded qualitative sub study will ex-
plore patients’ perceptions about the acceptability of
randomisation.
DANTE will follow a two-stage recruitment strategy
with registration of patients within 1 year of starting
standard of care, first line anti-PD-1 therapy and
Fig. 1 Summary of the DANTE trial
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randomisation of eligible patients after 1 year of this
treatment, which signifies the start of the clinical trial.
The ability to register patients for trial entry prior to
completion of 1 year of anti-PD-1 therapy and as such
prior to consideration of randomisation introduces trial
concepts early and aims to improve acceptance of subse-
quent randomisation. Registration also allows patients
who decline randomisation to be identified for a planned
qualitative assessment of reasons for patient acceptance
versus decline of randomisation to help improve ran-
domisation rates.
Trial aims and objectives
The study aims to identify if time-limited treatment of
anti-PD-1 therapies is non-inferior to standard treat-
ment for clinical efficacy outcomes and if time-limited
treatment can lead to improved quality of life and health
economic outcomes due to reduction in side effects and/
or reduced treatment burden.
Primary objective
The primary objective is to determine whether reduced
duration therapy is non-inferior to standard treatment in
terms of PFS.
Secondary objectives
Secondary objectives include quality of life (key second-
ary objective), overall survival, response after randomisa-
tion as defined by RECIST v1.1 criteria [23], safety and
drug-induced toxicity and cost-effectiveness.
Interim objectives
 To demonstrate an adequate rate of patient
recruitment and acceptance of randomisation (Stage 1)
 To confirm feasibility of the randomisation target
across all sites (Stage 2)
 To identify early evidence of lack of efficacy or even
superiority of time-limited treatment compared to
standard treatment (Stage 3).
Long-term follow-up objectives
 To determine whether time-limited treatment is
non-inferior in terms of PFS and OS at 4 years post-
randomisation compared to standard treatment
(Stage 4)
 To report long-term safety data of time-limited
treatment and standard treatment (Stage 5).
Trial population
DANTE aims to be representative of the current popula-
tion of adult (≥18 years) patients with advanced melan-
oma (unresectable stage III or stage IV) on first-line
anti-PD-1 therapy, either as single agent or in combin-
ation with ipilimumab. Recruitment therefore allows any
patient who meets these broad criteria and is within the
first 1 year of therapy to be registered.
For randomisation, which signals the start of the trial,
patients must still be on anti-PD-1 therapy, be progres-
sion free by RECIST v1.1 criteria [23] at 1 year +/− 4
weeks and have been registered into the study. Patients
must have ECOG performance status 0–2 and be con-
sidered fit to receive on-going anti-PD-1 treatment. Pre-
vious targeted therapy with BRAF/ MEK inhibitors is
permitted. Patients treated with (neo)adjuvant therapy
may be randomised if completed more than 6months
prior to start of anti-PD-1 therapy. Patients with brain
metastases are eligible if asymptomatic and/or not re-
quiring further treatment in untreated brain metastases
or if radiologically stable by MRI and/or not requiring
high dose corticosteroids (defined as > 10mg per day
prednisolone/ equivalents) in treated brain metastases.
To remain eligible patients must not meet any of the de-
fined exclusion criteria (severe co-morbidities including
severe autoimmune disease or pneumonitis; active infec-
tion requiring systemic therapy; known active HIV,
hepatitis B or hepatitis C; prior invasive cancer, exclud-
ing stage 1/2 non-melanoma skin cancer, without a dis-
ease free interval of 1-year after treatment completion;
pregnancy and/or breastfeeding). Patients must agree to
use adequate contraception whilst on anti-PD-1 therapy
and for 6 months after completion if of reproductive
potential (both male and female). All patients provide
written informed consent at registration and at
randomisation.
Recruitment, randomisation and treatment allocation
Patients are recruited at UK hospitals with specialist
melanoma oncology teams. Patient registration occurs at
any point from the start of anti-PD-1 therapy up until 1
year (+ 4 weeks).
Randomisation occurs at 1 year (+/− 4 weeks) post
start of anti-PD-1 therapy in eligible patients. Treatment
allocation via a central automated 24-h system (provided
by University of Leeds), using a 1:1 ratio is by minimisa-
tion, with a random element, stratifying for BRAF status
(wildtype, mutant, unknown), prior use of BRAF/MEK
inhibitor therapy for advanced melanoma (yes, no), prior
use of (neo)adjuvant immunotherapy (yes, no), disease
stage at start of anti-PD-1 treatment (unresectable stage
III or stage IV disease), brain metastases (yes, no),
ECOG performance status (0/1, 2), centre, treatment re-
ceived within the previous 1 year (ipilimumab-nivolu-
mab, nivolumab or pembrolizumab) and response after
the first 1 year of therapy defined according to RECIST
v1.1 criteria [23] (CR, PR, SD). No attempt at allocation
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concealment will occur due to practicalities of treatment
within arms.
Sample size
Sample size calculations are based on the primary time-
point of 2-year PFS, which is equivalent to 1 year post
randomisation. To inform these calculations, data from
CheckMate 067 was used which showed 43% and 37% of
patients were alive and progression free at 1 year and 2
years after the start of treatment respectively in the nivo-
lumab only arm, and 50% and 43% of patients alive and
progression free at 1 year and 2 years for those receiving
combination therapy [24]. This correlates with a relative
reduction in PFS of 14% from 1 year to 2 years. Given
that 100% of the DANTE randomised population will be
alive and progression free at 1 year after starting anti-
PD-1 therapy (i.e. at the point of randomisation), it is es-
timated that approximately 86% will be alive and pro-
gression free at 2 years on standard treatment (as used
in CheckMate 067 [24]). Defining non-inferiority as a re-
duction in 2 year PFS of no more than 6%, with 80%
power and a one-sided significance level of 5%, and ac-
counting for a 5% drop out rate, 1208 patients (604 per
arm) are required in total to test for this degree of non-
inferiority using a one-sided log-rank test. Consensus for
the non-inferiority margin was reached after discussions
within the National Cancer Research Institute (NCRI)
Skin Cancer Clinical Studies Group and patient
representatives.
Baseline (pre-randomisation) investigations
All patients undergo assessment as per the current UK
standard prior to the initiation of anti-PD-1 +/− CTLA-
4 therapy, including cross-sectional imaging. Repeat
cross-sectional imaging (within 28 days of randomisa-
tion) is undertaken and compared to the pre-treatment
baseline scan by RECIST v1.1 criteria [23] to ensure pro-
gression free status at randomisation. Baseline patient-
reported assessments of quality of life (QoL), using the
generic EORTC QLQ-C30 questionnaire [25] and the
melanoma-specific module EORTC QLQ-MEL38 [26]
and health care resource use, using EQ-5D-5L (EuroQol)
[27] are completed following consent but prior to
randomisation.
Intervention
At randomisation, patients allocated the control arm
(standard treatment) continue on the same treatment as
before and those allocated the experimental arm stop
treatment. Standard treatment continues for at least 2
years in the absence of disease progression, unacceptable
toxicity or patient choice to stop protocol treatment.
At progression, re-treatment with the same anti-PD-1
therapy may be considered providing strict criteria are
met in line with local commissioning arrangements.
Follow-up data collection
All data are collected on trial specific paper CRFs and
submitted to the Clinical Trials Research Unit (CTRU)
at the University of Leeds for management and
monitoring.
Patients who continue to receive anti-PD-1 therapy
within the control arm have regular toxicity assess-
ments, at least every 12 weeks and in line with
current practice at each trial site. Patients in both
arms are assessed for toxicity, concomitant medica-
tions and response every 3 months (+/− 2 weeks) for
1 year post randomisation and then every 6 months
(+/− 2 weeks) for up to 4 years post randomisation.
Cross-sectional CT/MRI imaging is performed at
these time points in accordance with standard prac-
tice, with assessment of the chest, abdomen and pel-
vis plus any known additional disease sites. In
patients without known brain metastases, imaging of
the head is performed at least 6 monthly. Toxicity is
graded using CTCAE v5.0 [28] and imaging reported
using RECIST v1.1 [23]. A schedule of assessment is
included as supplementary material (Additional file 1:
Table S1).
Patient-reported QoL [25,26] and health care resource
use [27] assessments are undertaken during clinic visits
or by post every 3months (+/− 2 weeks) for 18 months
post randomisation. This includes patients who have
progressed during this time period where possible. The
use of EQ-5D-5L (EuroQol) [27] for health care resource
use assessments will allow subsequent estimation of
quality adjusted life years (QALYs). Health economic
data (QALYs and costs) will allow estimation of the
within trial incremental cost effectiveness ratio (ICER) of
the two treatment arms. Using a de novo decision-
analytic model, trial outcomes will be extrapolated to
generate lifetime estimates of cost-effectiveness.
All patients are followed up until 4 years post random-
isation. In patients who have progressed, data on treat-
ment administered post-progression, toxicity and
survival will be collected at the planned time points
using paper case report forms (CRFs) where possible
and / or via routine data sources e.g. NHS Digital, Office
for National Statistics or Systemic Anti-Cancer Therapy
data-set.
Safety
Selected AEs related to anti-PD-1 therapy administered
before randomisation are reported for both arms. For
the control arm only, all adverse reactions (ARs) related
to anti-PD-1 therapy administered after randomisation
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are reported together with serious adverse reactions
(SARs) and suspected unexpected serious adverse reac-
tions (SUSARs) from randomisation to 5 months follow-
ing the last delivered protocol treatment.
Statistical methods and analysis
Stage 1 will take place following 9 months of recruit-
ment. The percentage of eligible patients that agree
to be randomised, from sites that have been open for
6 months, will be summarised. Pre-specified red,
amber and green targets have been set to make deci-
sions on trial continuation. The overall number of
randomisations from all sites will also be presented.
Stage 2 will assess the number of randomised partici-
pants from all sites within a defined 6 month period
of recruitment. Trial continuation decisions will be
made against a set of red, amber and green targets.
At stage 1 and 2, baseline and disease characteristics
will be summarised descriptively for the randomised
population and all registered patients who are alive
and progression-free at 12 months. Stage 3 analysis
will be performed on the intention-to-treat (ITT)
population and will test for early evidence of super-
iority (p < 0.005) or inferiority (p < 0.05) of the experi-
mental arm against the control arm on PFS. Different
alpha levels have been incorporated to reflect the
relative importance of the interim analysis for super-
iority and inferiority claims. PFS will be investigated
using Kaplan-Meier survival curves. Participants with-
out a PFS event at the time of analysis will be cen-
sored at the date they were last known to be alive
and progression-free. If the proportional hazards as-
sumption is met, Cox’s Proportional Hazards model,
adjusting for the minimisation factors, will be used to
compare PFS between the treatment arms.
Analysis of non-inferiority endpoints will be per-
formed on both the ITT and per-protocol populations;
equal weighting will be given to both analyses as ITT is
likely to be the least conservative approach when testing
for non-inferiority. Analysis of superiority endpoints will
be performed on an ITT basis with per-protocol analyses
conducted if there are a sufficient number of major
protocol violators; ITT analyses will however be given
primacy. Hypothesis testing will be two-sided for super-
iority endpoints and one-sided for non-inferiority end-
points and use a 5% significance level.
Interpretation of non-inferiority for the primary end-
point of PFS will be based on the 90% (one sided type I
error rate of 5%) confidence interval (CI) of the differ-
ence in PFS rates at 1 year post randomisation deter-
mined from Kaplan-Meier estimates at this time-point;
the upper limit of the 90% CI will be compared with the
non-inferiority margin of 6%. If it is below this margin
then time-limited treatment will be declared as non-
inferior to standard treatment. If the upper limit is above
the non-inferiority margin then non-inferiority will not
have been demonstrated. PFS and OS will be assessed
using Kaplan-Meier curves. If appropriate, Cox’s Propor-
tional Hazards model, adjusting for the minimisation
factors, will be used to compare PFS and OS between
the treatment groups. In addition, a sensitivity analysis
of the primary endpoint will assess time to progression,
where deaths without documented evidence of progres-
sion will be considered a competing-risk event. Time to
progression will be investigated using cumulative inci-
dence function curves and compared using Cox’s Pro-
portional Hazards model if appropriate, to adjust for the
minimisation factors.
The main QoL outcome of interest is the summary
score of the EORTC QLQ-C30 [29]. Quality of life will
be summarised at each time point using adjusted for
baseline mean scores and 95% CIs. Summaries and dif-
ferences between arms will be obtained and compared
using a multi-level repeated measures model, allowing
for time, treatment, and treatment-time interactions,
and adjusting for baseline QoL and the minimisation
factors (fixed effects) and participant and participant-
time interaction (random effects) where appropriate, as-
suming missing data at random. Missing data patterns
will be examined and alternative analyses using different
missing data assumptions will be performed if appropri-
ate (e.g. pattern mixture multi-level models). This meth-
odology will be repeated to analyse scores from the
EORTC QLQ-MEL38 [26].
Differences in response (defined by RECIST v1.1 cri-
teria [23]) rates between the treatment groups will be
compared using logistic regression for objective response
and ordered logistic regression for best tumour response,
adjusting for the minimisation factors. Sensitivity ana-
lyses will be conducted to allow for any deaths from
causes other than melanoma, for whom no response sta-
tus was observed. Both ITT and per-protocol analyses
will be performed on the RECIST evaluable population.
Duration of response will be assessed in only those par-
ticipants in the RECIST evaluable population who have a
response after randomisation; deaths without documented
evidence of disease progression will be considered a
competing-risk event. Duration of response will be investi-
gated using cumulative incidence function curves and
compared using Cox’s Proportional Hazards model if ap-
propriate, adjusting for the minimisation factors.
Subgroup analyses for the clinical randomisation fac-
tors and other baseline characteristics will be performed
to investigate whether there is heterogeneity of treat-
ment effect on outcomes.
Safety and toxicity will be reported descriptively. Two
sets of cost-effectiveness analyses will be undertaken for
the health economic evaluation: trial-based analyses,
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comparing costs and outcomes between time-limited and
standard treatment duration up to the 18-month post-
randomisation time-point; and decision-analytic model-
based analyses, which will extrapolate the results of the
trial over a lifetime horizon. Costs will incorporate time
on treatment; and social, primary and secondary health
care use costs. Unit prices will be applied to these based
on standard sources (e.g. Drugs and pharmaceutical elec-
tronic market information tool [eMIT] and NHS Refer-
ence costs). QALYs will be based on the EQ-5D-5L using
the approach to scoring currently preferred by NICE [30].
However, a new UK EQ-5D-5L valuation study is on-
going and we will use the resulting valuation tariff if it is
available at the time of analysis and providing the results
are valid and robust. The trial analyses will estimate ICERs
following adjustment for baseline imbalance and key mini-
misation factors. Parametric or non-parametric (i.e. boot-
strapping) methods will be used to characterise the
sampling uncertainty present with simulations plotted on
a cost-effectiveness plane and cost-effectiveness accept-
ability curves. We will assess the type and degree of miss-
ing data and evaluate whether the assumption of missing
at random (MAR) holds [31]. If that is the case, multiple
imputation will be used to impute missing data. Should
MAR not hold we will explore the impact of alternative
assumptions [32]. We will generate a detailed health eco-
nomic analysis plan (HEAP).
As the benefits of the interventions are expected to ex-
tend beyond the trial follow-up period, we will develop a
decision-analytic model to estimate future costs and bene-
fits following best practice [33]. The model type and struc-
ture will be agreed after consultation with clinical experts
and patients and a review of existing models in the area.
The model will enable the calculation of discounted
lifetime ICERs and estimates of net monetary benefit
(NMB). We will assume a cost-effectiveness threshold of
£20,000 per QALY gained. We will conduct extensive
deterministic one-way and scenario sensitivity analyses.
Monte Carlo simulations using draws from parameter
distributions will allow a probabilistic sensitivity analysis
capturing total parameter uncertainty in the model. Re-
sults from this will be presented in the form of cost-
effectiveness planes, NMB distributions and cost-
effectiveness acceptability frontiers [34]. Costs and bene-
fits post 12 months will be discounted at a rate of 3.5%
per annum as per NICE guidance.
Trial organisation and administration
The Clinical Trials Unit, on behalf of the trial sponsor,
ensure the trial is undertaken according to the principles
of Good Clinical Practice (GCP) and in line with the
relevant UK Research Governance Frameworks. Trial
registration is ISRCTN15837212 and the EudraCT num-
ber is 2017–002435-42.
An independent Data Monitoring and Ethics Commit-
tee (DMEC) review the safety and the ethics of the trial
with detailed unblinded interim reports submitted at
least annually. The DMEC, together with the Trial Steer-
ing Committee (TSC) and the funder are responsible for
enacting stop/ continuation rules during the interim
stages (stages 1 to 3) if predefined targets for patient re-
cruitment or efficacy are not met.
Sub-studies
To inform trial recruitment both now and in the future,
an integrated qualitative sub-study is included. This sub-
study will explore patients’ views on decision making
with regard to trial entry and subsequent randomisation.
A semi-structured topic guide facilitated exploration will
be undertaken for 24 patients eligible for registration (6
patients) or randomisation (18 patients, 2:1 ratio of ran-
domised to non-randomised patients). All interviews will
be audio recorded following informed consent and a the-
matic analysis [35] will be performed.
At recruitment, patients consent will be sought to pro-
vide access to any archival melanoma tumour samples,
to be used in future translational research.
The trial protocol and this paper have been written in
accordance with standard protocol items: recommenda-
tions for interventional trials (SPIRIT) guidelines [36]. A
SPIRIT checklist is included as supplementary material
(Additional file 2: Table S2).
Discussion
Given the implications to both patients and health care
systems across the world, there is a high international im-
perative to define optimal duration of therapy with anti-
PD-1 antibodies. Treatment-associated burden to patients
includes time, financial and potential drug induced tox-
icity whereas treatment-associated burden to healthcare
includes capacity, drug costs and associated treatment de-
livery costs. DANTE hopes to answer the question as to
whether continued treatment is justified accounting for
these costs or if time-limited treatment can provide
greater value without loss of treatment benefit.
To date, a single randomised trial, CheckMate 153,
has reported only exploratory data on the optimal dur-
ation of anti-PD-1 treatment. This trial randomised pa-
tients with advanced non-small cell lung cancer to
continuous and time-limited (1 year) nivolumab treat-
ment to evaluate the incidence of high-grade select
treatment AEs [37]. In this exploratory analysis, median
overall survival was not reached for continuous treat-
ment and was 23.2 months for time-limited treatment
[37]. The 1 year OS rate was not statistically different be-
tween the two groups (88% for continuous treatment vs.
81% for time-limited treatment with a HR = 0.63, 95% CI
0.33–1.20) [37]. In this study of 1375 patients, only 15%
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(n = 218) remained on nivolumab at 1 year and so the
number of patients eligible for randomisation was small
[37]. It is also arguable that due to different immunosen-
sitivities of different tumour types, the results are not
generalisable.
Two additional clinical trials are ongoing in metastatic
/ unresectable melanoma to evaluate the impact of stop-
ping treatment in patients upon achieving response:
STOP-GAP and Safe Stop-T.
The Canadian STOP-GAP study (NCT02821013) [38],
is a phase 3 trial which randomises eligible patients
within 16 weeks of starting anti-PD-1 therapy to stand-
ard treatment of 2 years or to treatment until maximal
tumour response (defined by at least 2 radiological mea-
surements 3 months apart) with re-treatment at time of
progression. STOP-GAP, designed to complete recruit-
ment at the end of 2023, therefore primarily aims to
evaluate the role of re-challenge rather than the specific
question of optimal treatment duration.
The Dutch Safe Stop Trial (Safe Stop-T, NTR7502
[39]) is an observational study of the STOP & GO strat-
egy of PD-1 blockade where treatment is stopped within
4 weeks of confirmation of radiological response (CR or
PR according to RECIST v1.1 criteria [23]). Radiological
monitoring continues every 12 weeks with treatment im-
mediately re-commenced in the event of progression.
The primary outcome measure is the rate of ongoing re-
sponse according to RECIST v1.1 criteria [23] at 2 years
after the start of PD-1 blockade. Further sub-studies in-
clude Safe Stop-QoL which evaluates the impact of this
early discontinuation of treatment on patient reported
disease specific and generic health-related QoL, patient
productivity and informal care resource use. Safe Stop-T
[39] therefore aims to provide observational data on the
safety of intermittent treatment in a cohort of 200 pa-
tients rather than identify the optimal duration of treat-
ment through a randomised trial.
A cohort study [40] in 185 patients with advanced
melanoma, across various treatment centres, who elec-
tively stopped anti-PD-1 therapy in the absence of pro-
gressive disease or treatment-limiting toxicity, provides
further observational data on the impact of early discon-
tinuation of anti-PD-1 treatment. In this study patients
who experienced a best objective response (BOR) of CR
during treatment (117 of 185) had a shorter median dur-
ation of anti-PD-1 therapy (11 months) and were signifi-
cantly less like to experience PD following treatment
discontinuation compared to those who experienced a
BOR of PR (HR 2.99, 95% CI 1.45–6.16) or a BOR of SD
(HR 5.15, 95% CI 2.19–12.09) [40]. This supports previ-
ously observed data that durable responses can continue
in patients who discontinue treatment earlier than a
planned duration of 2 years (as used in KEYNOTE-006
[20] and across many worldwide healthcare settings).
The observed difference in PD across the subgroups of
BOR poses the question of whether response during
treatment should be considered when decisions on dur-
ation of anti-PD-1 therapy are made on an individual pa-
tient basis. Future prospective studies to answer this
question are however required.
The DANTE trial will help define what constitutes the
optimal duration of anti-PD-1 therapy in the treatment of
advanced melanoma. Designed as a prospective rando-
mised controlled trial it will assess whether treatment
should be continued for a set time and specifically
whether this should for a reduced duration of 1 year. This
contrasts with STOP-GAP [38] and Safe Stop-T [39]
which will assess whether treatment should be continued
to a set response. All three trials are however key to
expanding the evidence base and ensuring patients receive
the correct duration of treatment, both in terms of efficacy
and costs, without being given too much or too little.
The outcomes of these studies will not only enable
better patient and clinician decision making on an indi-
vidual patient basis but ensure that continuation of these
high cost treatments remain appropriate in a high de-
mand, resource limited healthcare setting.
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